Kiyatec, a Greenville, SC-based precision oncology company, raised US$18M in Series C funding.
The round was led by Bruker (Nasdaq: BRKR) with participation from Seae Ventures, VentureSouth, and LabCorp (NYSE: LH).
The company intends to use the funds to accelerate adoption of its commercially available clinical testing and preclinical pharma services, which add value across the life cycle of successful cancer drugs.
Led by CEO Matt Gevaert, Kiyatec is a functional precision oncology company that measures the response of each patient’s live cancer cells to inform oncologists’ treatment selection decisions. Its Clinical Services offers clinical testing for high-grade glioma, and is developing assays for use in ovarian, breast, non-small cell lung cancers, and rare tumors in its CLIA certified lab. Its Drug Development Services works in partnership with biopharmaceutical companies to unlock response dynamics for their pre-clinical investigational drug candidates across the majority of solid tumor types.
Kiyatec’s analytically validated 3D-Predict™ Glioma test informs therapy selection in the clinic for glioblastoma (GBM) and other high grade glioma patients and is commercially available (US but not in CA, NY or RI at this time).
FinSMEs
12/12/2022